相关实验视频
Updated: Aug 16, 2026
08:20
A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
Published on: October 2, 2018
11.8K
避孕药引起的损伤:对Levonorgestrel和DMPA的动物模型研究
F A Akinpelu1,2, O L Apanisile3, B M Oguntimilehin4
1Department of Anatomy, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria.
JBRA assisted reproduction
|October 8, 2025
概括
激素避孕药,如Levonorgestrel和Depot-Medroxyprogesterone乙酸破坏动物的雌激素周期,并减少交配成功和 litter 尺寸,表明潜在的生育能力受损.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 激素避孕药的药理学 激素避孕药的药理学
- 生殖研究中的动物模型.
背景情况:
- 荷尔蒙避孕药调节下丘脑-垂体-腺 (HPG) 轴以防止怀孕.
- 了解它们对动物模型中雌性循环和生育能力的影响对于评估避孕机制和生殖结果至关重要.
研究的目的:
- 为了研究Levonorgestrel和Depot-Medroxyprogesterone乙酸 (DMPA) 对Wistar大鼠雌激素周期阶段的影响.
- 评估这些避孕药对荷尔蒙平衡,交配成功和生育能力的影响.
- 提供关于避孕疗法的有效性和潜在的长期生殖后果的见解.
主要方法:
- 15只成年雌性Wistar大鼠被分为三个组:对照组,接受Levonorgestrel治疗的组和接受DMPA治疗的组.
- 用阴道细胞学来监测治疗前,治疗期间和治疗后的雌性周期阶段.
- 通过评估怀孕率和幼大小来评估交配成功和生育能力.
主要成果:
- 莱沃诺格斯特雷尔和DMPA都显著破坏了雌性周期的规律性,缩短了雌性阶段,延长了雌性阶段.
- 与对照组 (100%) 相比,治疗组 (40-60%) 的交配成功显著降低.
- 与对照组相比,接受Levonorgestrel或DMPA治疗的女性的子数量明显较低.
结论:
- 长时间使用Levonorgestrel或DMPA可以显著改变动物的雌性循环.
- 这些荷尔蒙避孕药可能会损害生育能力并延迟生殖能力的恢复.
- 需要进一步的研究来阐明避孕药诱导的生殖周期中断的长期影响.
相关概念视频
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).